There hasn't been a specific discussion around the issue of amphetamines with regard to the pharmaceutical industry paying for treatment or other services related to that. As you know, there have been a number of discussions happening in the area of opioids and ensuring that we are restricting the marketing ability of pharmaceutical companies associated with that.
On November 29th, 2018. See this statement in context.